FindTrial
Sign In

An Open-label Controlled Trial to Assess the Prophylactic Efficacy of N-Acetylcysteine on Radio-contrast Induced Nephropathy in Patients With Advanced Chronic Kidney Disease Planned to Start Dialysis Therapy

An Open-label Controlled Trial to Assess the Prophylactic Efficacy of N-Acetylcysteine on Radio-contrast Induced Nephropathy in Patients With Advanced Chronic Kidney Disease Planned to Start Dialysis Therapy - Prophylactic Efficacy of N-Acetylcysteine(NAC) on Radio-contrast Induced Nephropathy(RCIN) in Patients With Advanced Chronic Kidney Disease(CKD) Planned to Start Dialysis Therapy

Status
Unknown
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000000581
Enrollment
40
Registered
2007-02-01
Start date
2007-02-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with advanced CKD planned to dialysis therapy

Interventions

Oral administration of N-Acetylcysteine Saline infusion at a rate of 1 ml/kg/hour for 12 hours before and after radiocontrast agent administration

Sponsors

Department of Nephrology, Rinku General Medical Center Izumisano Municipal Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Inpatients planned to start dialysis therapy and to be examined by coronary angiography or radiocontrast-enhanced computed tomography

Exclusion criteria

Exclusion criteria: 1)Contraindicated to radiocontrast agent or N-Acetylcysteine 2)Malignancy 3)Congestive heart failure(NYHA III, IV) 4)Acute myocardial infarction, pulmonary embolism and cerebral infarction within 6 months 5)Diastolic blood pressure of 100 mmHg or more

Design outcomes

Primary

MeasureTime frame
Change in creatinine clearance, serum creatinine and urine volume during two weeks after radio-contrast agent administration—

Secondary

MeasureTime frame
Change in residual renal function after induction of dialysis therapy—

Countries

Japan

Contacts

Public ContactTerumasa Hayashi

Rinku General Medical Center, Izumisano Municipal Hospital Department of Nephrology

t-hayashi@rgmc.izumisano.osaka.jp072-469-3111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026